Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial

被引：0

作者：

David A Palma

Cornelis J A Haasbeek

George B Rodrigues

Max Dahele

Michael Lock

Brian Yaremko

Robert Olson

Mitchell Liu

Jason Panarotto

GwendolynHMJ Griffioen

Stewart Gaede

Ben Slotman

Suresh Senan

机构：

[1] London Regional Cancer Program,Department of Radiation Oncology

[2] VU University Medical Center,Department of Radiation Oncology

[3] British Columbia Cancer Agency,Department of Radiation Oncology

[4] Ottawa Regional Cancer Centre,Department of Radiation Oncology

来源：

BMC Cancer | / 12卷

关键词：

Oligometastases; Stereotactic radiotherapy; Quality of life; Cancer; Survival;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[31] A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol
Palma, David A.
Giuliani, Meredith E.
Correa, Rohann J. M.
Schneiders, Famke L.
Harrow, Stephen
Guckenberger, Matthias
Zhang, Tina
Bahig, Houda
Senthi, Sashendra
Chung, Peter
Olson, Robert
Lock, Michael
Raman, Srinivas
Bauman, Glenn S.
Lok, Benjamin H.
Laba, Joanna M.
Glicksman, Rachel M.
Nguyen, Timothy K.
Lang, Pencilla
Helou, Joelle
Goodman, Christopher D.
Mendez, Lucas C.
van Rossum, Peter S. N.
Warner, Andrew
Gaede, Stewart
Allan, Alison L.
BMC PALLIATIVE CARE, 2024, 23 (01):
[32] Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiotherapy for Oligometastatic Disease: A Secondary Analysis of the Phase II SABR-5 Trial
Kooyman, A.
Chang, J. S.
Liu, M.
Jiang, W.
Bergman, A.
Schellenberg, D.
Mou, B.
Alexander, A. S.
Carolan, H.
Hsu, F.
Atrchian, S.
Chan, E. K.
Berrang, T.
Chng, N.
Matthews, Q.
Pai, H. H.
Valev, B.
Tyldesley, S.
Olson, R. A.
Baker, S.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : S26 - S26
[33] EVALUATING TOXICITY AND INTERACTION OUTCOMES OF SYSTEMIC THERAPY AND STEREOTACTIC ABLATIVE RADIOTHERAPY FOR OLIGOMETASTATIC DISEASE: A SECONDARY ANALYSIS OF THE PHASE II SABR-5 TRIAL
Kooyman, Aiden
Chang, Jee Suk
Liu, Mitchell
Jiang, Will
Bergman, Alanah
Schellenberg, Devin
Mou, Benjamin
Alexander, Abraham
Carolan, Hannah
Hsu, Fred
Miller, Stacy
Atrchian, Siavash
Chan, Elisa
Ho, Clement
Mohamed, Islam
Lin, Angela
Berrang, Tanya
Bang, Andrew
Chng, Nick
Matthews, Quinn
Huang, Vicky
Mestrovic, Ante
Hyde, Derek
Lund, Chad
Pai, Howard
Valev, Boris
LeFresne, Shilo
Tyldesley, Scott
Olson, Robert
Baker, Sarah
RADIOTHERAPY AND ONCOLOGY, 2024, 198 : S36 - S36
[34] Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5
Robert Olson
Mitchell Liu
Alanah Bergman
Sonya Lam
Fred Hsu
Benjamin Mou
Tanya Berrang
Ante Mestrovic
Nick Chng
Derek Hyde
Quinn Matthews
Chad Lund
Daniel Glick
Howard Pai
Parminder Basran
Hannah Carolan
Boris Valev
Shilo Lefresene
Scott Tyldesley
Devin Schellenberg
BMC Cancer, 18
[35] Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5
Olson, Robert
Liu, Mitchell
Bergman, Alanah
Lam, Sonya
Hsu, Fred
Mou, Benjamin
Berrang, Tanya
Mestrovic, Ante
Chng, Nick
Hyde, Derek
Matthews, Quinn
Lund, Chad
Glick, Daniel
Pai, Howard
Basran, Parminder
Carolan, Hannah
Valev, Boris
Lefresene, Shilo
Tyldesley, Scott
Schellenberg, Devin
BMC CANCER, 2018, 18
[36] Dosimetric Predictors of Local Control after Stereotactic Ablative Radiotherapy (SABR) for Lung Tumors: A Secondary Analysis of a Phase II Prospective Trial of Individualized SABR (iSABR)
Wu, Yufan Fred
Lau, Brianna
Fu, Jie
Skinner, Lawrie
Gensheimer, Michael
Gee, Harriet
Diehn, Maximilian
Loo, Billy
Chin, Alex
Vitzthum, Lucas
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2022, 45 (09): : S16 - S16
[37] POPULATION BASED PHASE II TRIAL OF STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) FOR UP TO FIVE OLIGOMETASTASES: PRELIMINARY RESULTS OF THE SABR-5 TRIAL
Olson, Robert
Jiang, Will
Liu, Mitchell
Bergman, Alanah
Schellenberg, Devin
Mou, Benjamin
Alexander, Abraham
Carolan, Hannah
Hsu, Fred
Miller, Stacy
Atrchian, Siavash
Chan, Elisa
Ho, Clement
Mohamed, Islam
Lin, Angela
Berrang, Tanya
Bang, Andrew
Chng, Nick
Matthews, Quinn
Mestrovic, Ante
Hyde, Derek
Huang, Vicky
Lund, Chad
Pai, Howard
Valev, Boris
Lefresne, Shilo
Tyldesley, Scott
RADIOTHERAPY AND ONCOLOGY, 2021, 163 : S4 - S4
[38] Population Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for up to 5 Oligometastases: Preliminary Results of the SABR-5 Trial
Olson, R. A.
Jiang, W.
Liu, M. C.
Bergman, A.
Schellenberg, D.
Mou, B.
Alexander, A. S.
Carolan, H.
Hsu, F.
Miller, S.
Atrchian, S.
Chan, E. K.
Ho, C.
Mohamed, I. G.
Lin, A.
Berrang, T.
Bang, A.
Chng, N.
Matthews, Q.
Huang, V.
Mestrovic, T.
Hyde, D.
Lund, C. R.
Pai, H. H.
Valev, B.
Lefresne, S.
Tyldesley, S.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S4 - S4
[39] Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors
Chaudhuri, Aadel A.
Tang, Chad
Binkley, Michael S.
Jin, Michelle
Wynne, Jacob F.
von Eyben, Rie
Hara, Wendy Y.
Trakul, Nicholas
Loo, Billy W., Jr.
Diehn, Maximilian
LUNG CANCER, 2015, 89 (01) : 50 - 56
[40] A Phase 1 Trial of Stereotactic Ablative Radiation Therapy (SABR) for Oligometastatic Cancer: Toxicity and Quality of Life
Erler, D.
Cheung, P.
Sahgal, A.
Chung, H. T.
Poon, I.
Chu, W.
Zhang, L.
Bedard, G.
Pulenzas, N.
Chow, E.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E492 - E492

← 1 2 3 4 5 →